“… Human peripheral blood mononuclear cells [from 16 subjects (9 males, 7 females, age 23.5 ± 3.8 years) who donated blood] | LPS and PHA antigen | E. laevigata, E. angustifolia, E. pallida, and E. purpurea | Root tinctures of each species extracted in 50% EtOH/50% cell culture water at a ratio of 1:9 parts plant material:solvent. Dose: 50 μL/well DURATION: 24, 48 or 72 h | Negative control: no treatment Positive control: LPS and PMA antigen | Increased levels: IL-10 and TNF-α No change in levels: IL-2 | 1 | Sharma, 2006 [ 109 ] | Not stated | The tracheo-bronchial line BEAS-2B and the rhinovirus-sensitive H-1 derivative of HeLa cells | Rhinovirus type 14 | E. purpurea | Two extracts: E1: an expressed juice extract of the aerial parts of E. purpurea E2: a 50% alcoholic tincture, derived from E. purpurea roots (1:9 w/v) Dose: 100 μg/mL of E1 or 50 μg/mL of E2 DURATION: 24–96 h | Negative control: no treatment on uninfected cells Positive control: no treatment on virally infected cells | Increased secretion: IL-1β, IL-2, IL-3, and IL-7 Decreased secretion: IFN-γ, IL-1⍺, IL-1β, IL-2, IL-3, IL-5, IL-6, IL-7, IL-8, IL-15, IL-17, TNF-α, GM-CSF, CCL8, CCL10, CCL11, MIP-1α, MIP1β and MIP-4 | 3 |
Sharma, 2009 [ 110 ] | Not stated | The tracheo-bronchial line BEAS-2B, H-1 sub clone of HeLa cells, the lung-derived epithelial cell line A549, and human skin fibroblasts | Rhinovirus types 1A and 14 | E. purpurea | Echinaforce by A. Vogel Bioforce AG, Switzerland: a 65% ethanol extract of freshly harvested aerial parts supplemented with 5% roots. Dose: dilutions of 1:20, 1:100, 1:200, and 1:400 DURATION: 48 h | Negative control: no treatment on uninfected cells Positive control: no treatment on virally infected cells | Decreased secretion: IL-6 and IL-8 | 3 |
Sharma, 2009 [ 111 ] | Not stated | Two human epithelial cell lines: the tracheo-bronchial line BEAS-2B and the lung-derived epithelial cell line A549 as well as human skin fibroblasts | Viruses: RV1A, RV14, influenza, RSV, adenovirus types 3 and 11, and HSV | E. purpure... |
…”